Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial - Concepedia

Concepedia

Publication | Open Access

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

DOI Full Paper Access

54

Citations

34

References

2023

Year

Komal Jhaveri, L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni, Adam Brufsky, H. Park, James Waisman, Eddy S. Yang,

Annals of Oncology

References

	Year	Citations

Page 1